Experienced in Ulcerative Colitis

Lijuan J. Huo

85 Jie Fang South Road, 
Taiyuan, CN 
Experienced in Ulcerative Colitis
85 Jie Fang South Road, 
Taiyuan, CN 
OverviewLocationsClinical Research

Overview

Lijuan Huo practices in Taiyuan, China. Huo is rated as an Experienced expert by MediFind in the treatment of Ulcerative Colitis. Their top areas of expertise are Cirrhosis, Helicobacter Pylori Infection, Peptic Ulcer, and Hepatitis B.

Their clinical research consists of co-authoring 27 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Ulcerative Colitis.

Locations

85 Jie Fang South Road, Taiyuan, 030001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2021
Intervention Type: Drug
Study Drug: Entecavir
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

27 Total Publications

Interleukin-22 ameliorates alcohol-associated liver fibrosis via Nrf2-ARE signaling: mechanistic insights and clinical correlations.
Interleukin-22 ameliorates alcohol-associated liver fibrosis via Nrf2-ARE signaling: mechanistic insights and clinical correlations.
Journal: Clinics and research in hepatology and gastroenterology
Published: March 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Huo's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile